Triple-negative breast cancer (TNBC)
Showing 1 - 25 of >10,000
TNBC - Triple-Negative Breast Cancer Trial (Camrelizumab Plus Chemotherapy and Famitinib, Camrelizumab Plus Chemotherapy)
Not yet recruiting
- TNBC - Triple-Negative Breast Cancer
- Camrelizumab Plus Chemotherapy and Famitinib
- Camrelizumab Plus Chemotherapy
- (no location specified)
Aug 17, 2023
Breast Cancer, Contrast Enhanced Ultrasound Trial in Hershey (Lumason)
Not yet recruiting
- Breast Cancer
- Contrast Enhanced Ultrasound
-
Hershey, PennsylvaniaPenn State Health College of Medicine
Jul 19, 2023
Breast Cancer Trial in Houston (Sacituzumab Govitecan, Pembrolizumab)
Not yet recruiting
- Breast Cancer
- Sacituzumab Govitecan
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Dec 22, 2022
BRCA and NACT in TNBC Patients
Completed
- Triple-Negative Breast Cancer
- BRCA1/2 genetic testing
-
Rome, RM, ItalyFondazione Policlinico Universitario Agostino Gemelli IRCCS
Feb 20, 2023
Triple Negative Breast Tumors Trial in Paris (Atezolizumab + RP1)
Not yet recruiting
- Triple Negative Breast Neoplasms
- Atezolizumab + RP1
-
Paris, FranceInstitut Curie
Oct 2, 2023
Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of
Not yet recruiting
- Triple Negative Breast Cancer
- +2 more
- Everolimus
- Investigator's Choice of Chemotherapy
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 25, 2023
Metastatic Triple-Negative Breast Cancer Trial in Charlotte (Trilaciclib, Pembrolizumab, Gemcitabine)
Not yet recruiting
- Metastatic Triple-Negative Breast Cancer
- Trilaciclib
- +3 more
-
Charlotte, North CarolinaLevine Cancer Institute
Aug 31, 2023
Triple Negative Breast Cancer Trial in Chengdu (Camrelizumab, Apatinib, Nab-paclitaxel)
Not yet recruiting
- Triple Negative Breast Cancer
- Camrelizumab
- +4 more
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Jul 6, 2022
Metastatic Triple-negative Breast Cancer Trial in Wuhan (Surufatinib, Tislelizumab)
Not yet recruiting
- Metastatic Triple-negative Breast Cancer
-
Wuhan, Hubei, ChinaTongji Hospital Affiliated of Tongji Medical College Huazhong Un
Feb 27, 2023
Metastatic Breast Cancer Trial in Shanghai (Sitravatinib, Tislelizumab, Nab-paclitaxel)
Recruiting
- Metastatic Breast Cancer
- Sitravatinib
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer
Jul 31, 2022
Triple Negative Breast Cancer (TNBC) Trial in El Segundo (Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl)
Withdrawn
- Triple Negative Breast Cancer (TNBC)
- Leucovorin
- +15 more
-
El Segundo, CaliforniaChan Soon-Shiong Institute for Medicine
Mar 28, 2022
Triple Negative Breast Cancer Trial (Ociperlimab, Tislelizumab, Paclitaxel)
Not yet recruiting
- Triple Negative Breast Cancer
- Ociperlimab
- +7 more
- (no location specified)
Mar 30, 2023
Triple Negative Breast Cancer, Metastatic Breast Cancer Trial in Boston (Pembrolizumab, PVX-410)
Active, not recruiting
- Triple Negative Breast Cancer
- Metastatic Breast Cancer
- Pembrolizumab
- PVX-410
-
Boston, Massachusetts
- +2 more
Dec 21, 2022
Triple Negative Breast Cancer, Brain Metastases Trial in Saint Louis (Pembrolizumab, Liposomal Irinotecan)
Recruiting
- Triple Negative Breast Cancer
- Brain Metastases
- Pembrolizumab
- Liposomal Irinotecan
-
Saint Louis, MissouriWashington University School of Medicine
Jun 1, 2022
Breast Cancer Trial in Amsterdam (Nivolumab, Radiation therapy, Low dose doxorubicin)
Active, not recruiting
- Breast Cancer
- Nivolumab
- +4 more
-
Amsterdam, NetherlandsAntoni van Leeuwenhoek
Mar 21, 2022
Triple Negative Breast Cancer (TNBC) Trial in United States (Combination of liposomal doxorubicin)
Not yet recruiting
- Triple Negative Breast Cancer (TNBC)
- Combination of liposomal doxorubicin
-
Elizabeth, New Jersey
- +7 more
Jul 13, 2023
Metastatic Breast Cancer Trial in Amsterdam (Nivolumab, Cisplatin, Low dose doxorubicin)
Recruiting
- Metastatic Breast Cancer
- Nivolumab
- +2 more
-
Amsterdam, NetherlandsAntoni van Leeuwenhoek
Mar 21, 2022
Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer Trial in Tampa (Dendritic Cell Vaccine)
Recruiting
- Leptomeningeal Disease
- +2 more
- Dendritic Cell Vaccine
-
Tampa, FloridaMoffitt Cancer Center
Apr 11, 2023
Triple Negative Breast Cancer (TNBC) Trial in China (B013+Nab-Paclitaxel)
Recruiting
- Triple Negative Breast Cancer (TNBC)
-
Guangzhou, Guangdong, China
- +6 more
Jan 29, 2023
Immunotherapy-related CRP Kinetics in Early and Metastatic
Recruiting
- TNBC - Triple-Negative Breast Cancer
-
Tuebingen, GermanyDepartment of Women's Health
Jun 13, 2023
Edema, Erythema, Estrogen Receptor Negative Trial in Houston (Laboratory Biomarker Analysis, Pembrolizumab)
Active, not recruiting
- Edema
- +8 more
- Laboratory Biomarker Analysis
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Jan 23, 2023
Triple Negative Breast Cancer Trial in Shanghai (Camrelizumab Plus Chemotherapy, +chemo)
Recruiting
- Triple Negative Breast Cancer
- Camrelizumab Plus Chemotherapy
- placebo+chemotherapy
-
Shanghai, ChinaFudan University Cancer Hospital
Feb 9, 2022
Breast Cancer Trial in Shanghai (ABX, cisplatin, Gemcitabine, Cisplatin)
Completed
- Breast Cancer
- ABX, cisplatin
- Gemcitabine, Cisplatin
-
Shanghai, ChinaFudan University Cancer Hospital
Apr 20, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Terminated
- Anatomic Stage IV Breast Cancer AJCC v8
- +2 more
- Bintrafusp Alfa
- Eribulin Mesylate
-
Houston, Texas
- +1 more
Oct 27, 2022